Rodrigues Lígia R, Teixeira José A, Schmitt Fernando L, Paulsson Marie, Lindmark-Mänsson Helena
Institute for Biotechnology and Bioengineering, Centre of Biological Engineering, Campus de Gualtar, 4710-057 Braga, Portugal.
Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1087-97. doi: 10.1158/1055-9965.EPI-06-1008.
The use of cancer biomarkers to anticipate the outlines of disease has been an emerging issue, especially as cancer treatment has made such positive steps in the last few years. Progress in the development of consistent malignancy markers is imminent because advances in genomics and bioinformatics have allowed the examination of immense amounts of data. Osteopontin is a phosphorylated glycoprotein secreted by activated macrophages, leukocytes, and activated T lymphocytes, and is present in extracellular fluids, at sites of inflammation, and in the extracellular matrix of mineralized tissues. Several physiologic roles have been attributed to osteopontin, i.e., in inflammation and immune function, in mineralized tissues, in vascular tissue, and in kidney. Osteopontin interacts with a variety of cell surface receptors, including several integrins and CD44. Binding of osteopontin to these cell surface receptors stimulates cell adhesion, migration, and specific signaling functions. Overexpression of osteopontin has been found in a variety of cancers, including breast cancer, lung cancer, colorectal cancer, stomach cancer, ovarian cancer, and melanoma. Moreover, osteopontin is present in elevated levels in the blood and plasma of some patients with metastatic cancers. Therefore, suppression of the action of osteopontin may confer significant therapeutic activity, and several strategies for bringing about this suppression have been identified. This review looks at the recent advances in understanding the possible mechanisms by which osteopontin may contribute functionally to malignancy, particularly in breast cancer. Furthermore, the measurement of osteopontin in the blood or tumors of patients with cancer, as a way of providing valuable prognostic information, will be discussed based on emerging clinical data.
利用癌症生物标志物来预测疾病概况已成为一个新出现的问题，尤其是在过去几年癌症治疗取得了如此积极进展的情况下。由于基因组学和生物信息学的进步使得能够对海量数据进行检测，一致的恶性肿瘤标志物的开发进展即将到来。骨桥蛋白是一种由活化的巨噬细胞、白细胞和活化的T淋巴细胞分泌的磷酸化糖蛋白，存在于细胞外液、炎症部位以及矿化组织的细胞外基质中。骨桥蛋白具有多种生理作用，即在炎症和免疫功能、矿化组织、血管组织以及肾脏中发挥作用。骨桥蛋白与多种细胞表面受体相互作用，包括几种整合素和CD44。骨桥蛋白与这些细胞表面受体的结合会刺激细胞黏附、迁移和特定的信号传导功能。在包括乳腺癌、肺癌、结直肠癌、胃癌、卵巢癌和黑色素瘤在内的多种癌症中都发现了骨桥蛋白的过表达。此外，一些转移性癌症患者的血液和血浆中骨桥蛋白水平升高。因此，抑制骨桥蛋白的作用可能具有显著的治疗活性，并且已经确定了几种实现这种抑制的策略。这篇综述探讨了在理解骨桥蛋白可能在功能上促进恶性肿瘤，特别是在乳腺癌中发挥作用的可能机制方面的最新进展。此外，将基于新出现的临床数据讨论在癌症患者的血液或肿瘤中检测骨桥蛋白，作为提供有价值的预后信息的一种方式。
